Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 651 - 675 of 14685 in total
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). ... causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta...
Approved
Investigational
Matched Description: … Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other ... [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure ... [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are …
Matched Categories: … valsartan and nebivolol ... nebivolol and thiazides ... nebivolol and amlodipine ... zofenopril and nebivolol ... Beta Blocking Agents and Thiazides …
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.
Approved
Investigational
Withdrawn
Matched Description: … Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
Approved
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is...
Approved
Investigational
Matched Description: … Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also ... , including carcinoid tumors and vasoactive intestinal tumors (VIPomas). ... Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatostatin and Analogues …
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Approved
Investigational
Vet approved
Matched Description: … Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … The active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine ... in the United States however it is available in several other countries including European countries and ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. It is one of the peroxy acid salts with very wide functionalities in industrial settings. Perboric acid in the form of sodium perborate is approved by Health Canada...
Approved
Matched Description: … Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate …
Matched Categories: … Alimentary Tract and Metabolism ... Antiinfectives and Antiseptics for Local Oral Treatment …
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296- ... It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Food and Drug Administration. ... a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and ... complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved...
Approved
Matched Description: … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and ... erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intracellular Signaling Peptides and Proteins …
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … , disrupting communication between the brain and other parts of the body. ... Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system ... fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Matched Description: … [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Matched Description: … antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and ... Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare ... Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within...
Approved
Experimental
Investigational
Matched Description: … It specifically replicates within tumor cells and causes lysis. ... laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and ... that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Matched Description: … It is an anticoagulant and considered an antithrombotic. ... It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. ... Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally...
Approved
Investigational
Matched Description: … Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha ... and working memory. ... the most effective and widely used treatment for ADHD, and are considered first-line options for children …
Matched Categories: … Methylphenidate and isomer ... Respiratory and CNS Stimulants ... Psychostimulants, Agents Used for ADHD and Nootropics …
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia. …
Matched Categories: … quinethazone and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... metformin and ertugliflozin ... sitagliptin and ertugliflozin …
A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Approved
Matched Description: … A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. ... It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. …
Matched Categories: … Beta Blocking Agents and Thiazides ... Antiglaucoma Preparations and Miotics ... metipranolol and thiazides, combinations ... Beta Blocking Agents, Non-Selective, and Thiazides …
Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and ... L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and ... Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. ... [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 651 - 675 of 14685 in total